A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors
| العنوان: | A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors |
|---|---|
| المؤلفون: | Gietema, JA, Hoekstra, R (Rosa), de Vos, FYFL, de Vries, EGE, Uges, DRA, van der Gaast, Ate, Groen, HJM, Loos, Walter, Knight, RA, Karyekar, CS, Daskowski, D, McKeegan, E, Knight, R, Humerickhouse, R, Verweij, Jaap, Eskens, Ferry |
| المساهمون: | Groningen Research Institute of Pharmacy, Damage and Repair in Cancer Development and Cancer Treatment (DARE), Guided Treatment in Optimal Selected Cancer Patients (GUTS), Medical Oncology |
| المصدر: | Annals of Oncology, 17(8), 1320-1327. Oxford University Press Annals of Oncology, 17, 1320-1327. Elsevier Ltd. |
| بيانات النشر: | Elsevier BV, 2006. |
| سنة النشر: | 2006 |
| مصطلحات موضوعية: | Adult, Male, Bevacizumab, CELL LUNG-CANCER, medicine.medical_treatment, BEVACIZUMAB, cisplatin, Angiogenesis Inhibitors, PACLITAXEL, Pharmacology, Deoxycytidine, LEUCOVORIN, Thrombospondin 1, Pharmacokinetics, Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Humans, Medicine, Drug Interactions, Aged, Cisplatin, Chemotherapy, business.industry, gemcitabine, ABT-510, Hematology, Middle Aged, phase I, Chemotherapy regimen, RANDOMIZED-TRIAL, FLUOROURACIL, Gemcitabine, SU5416, METASTATIC COLORECTAL-CANCER, angiogenesis inhibitor, Oncology, Fluorouracil, Female, business, Oligopeptides, medicine.drug |
| الوصف: | Background: The aim of the study was to determine the safety profile, pharmacokinetics and potential drug interactions of the angiogenesis inhibitor ABT-510 combined with gemcitabine-cisplatin chemotherapy in patients with solid tumors.Patients and methods: Patients with advanced solid tumors received gemcitabine 1250 mg/m(2) intravenously (i.v.) on days 1 and 8 and cisplatin 80 mg/m(2) on day 1 of a 3-week cycle in combination with ABT-510. ABT-510 was administered subcutaneously twice daily at doses of 50 mg or 100 mg. Plasma samples for pharmacokinetics were obtained on days 1 (gemcitabine, cisplatin as single agents), 15 (ABT-510 as single agent) and 22 (gemcitabine, cisplatin and ABT-510 as combination).Results: Thirteen patients received ABT-510 as either 50 mg b.i.d. (seven patients) or 100 mg b.i.d. (six patients) in combination with gemcitabine-cisplatin. The most common reported adverse events reflected the known toxicity profile induced by gemcitabine-cisplatin without ABT-510. One episode of hemoptysis occurred in a patient with non-small-cell lung cancer (NSCLC) after 13 days of treatment. No clinically significant pharmacokinetic interactions between ABT-510, gemcitabine and platinum were observed. Three partial responses were observed in 12 evaluable patients (one head and neck cancer, one melanoma and one NSCLC).Conclusions: Combining ABT-510 at doses of 50 mg and 100 mg with gemcitabine-cisplatin is feasible. Pharmacokinetic interactions were not observed and adding ABT-510 does not appear to increase toxicity. |
| تدمد: | 0923-7534 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d734c24e74dad1fadaf87c42dad5b107 https://doi.org/10.1093/annonc/mdl102 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....d734c24e74dad1fadaf87c42dad5b107 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 09237534 |
|---|